References
- Bjornsson T. D., Mahony C. Clinical pharmacokinetics of dipyridamole. Thrombosis Research 1983; IV: 93–104, (Supplement)
- Bochner F., Williams D. B., Morris P. M. A., Siebert D. M., Lloyd J. V. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man and effects on platelet function. European Journal of Clinical Pharmacology 1988; 25: 287–294
- Brantmark B., Wahlin-Boll E., Melander A. Bioavailability of acetyl-salicylic acid and salicylic acid from rapid and slow release formulations, and in combination with dipyridamole. European Journal of Clinical Pharmacology 1982; 22: 309–314
- Buchanan M. R., Rosenfeld J., Gert M., Lawrence W., Hirsch J. Dipyridamole plasma concentrations with salicylate administration. Relationship to effects on platelet aggregation in vivo. Thrombosis Research 1979; 15: 813–820
- Fassio G., Albizzati M. G., Bassi S., Frattola L. An investigation of the effect on platelet function of acetylsalicylic acid, dipyridamole and the two drugs in combination in patients with transient attacks of ischaemia. Journal of International Medical Research 1979; 7: 492–501
- Gregov D., Jenkins A., Duncan E., Siebert D., Rodgers S., Duncan B., Bochner F., Lloyd J. Dipyridamole pharmacokinetics and effects on aspects of platelet function in man. British Journal of Clinical Pharmacology 1987; 24: 425–434
- Klimt C. R., Stamler J., Knatterud G. L., Paris Research Group. Final results of the Persantin-aspirin reinfarction study (PARIS). Thrombosis and Haemostatis 1983; 54: 8
- Klimt C. R., Knatterud G. L., Stamler J., Meier P. Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. Journal of the American College of Cardiology 1986; 7: 251–269
- Lehmann C. R., Loche K., Shafler P. J., Pierson W. P. Persantin bioavailability problems. Clinical Pharmacy 1984; 3: 14–15
- Lowenthal A. Secondary prevention of myocardial infarction in the first European stroke prevention study. Thrombosis Research 1990; XII: 59–63, (Supplement)
- Lui C. Y., Oberle R., Fleisher D., Amidon G. L. Application of a radiotelemetric system to evaluate the performance of enteric-coated and plain aspirin tablets. Journal of Pharmaceutical Sciences 1986; 75: 469–474
- Mahony C., Wolfman K. M., Cocchetto D. M., Bjornsson T. D. Dipyridamole kinetics. Clinical Pharmacology and Therapeutics 1982; 31: 330–338
- Rajah S. M., Penny A. F., Cow M. J., Pepper M. D., Watson D. A. The interaction of varying doses of dipyridamole and acetylsalicylic acid on the inhibition of platelet functions and their effect on the bleeding time. British Journal of Clinical Pharmacology 1979; 8: 483–489
- Roberts M. S., McLeod L. J., Cossum P. A., Vial J. H. Inhibition of platelet function by a controlled release acetylsalicylic acid formulation—single and chronic dosing. European Journal of Clinical Pharmacology 1984; 27: 67–74
- Rosenfeld J., Buchanan M. R., Reilly P. A. Dipyridamole disposition after chronic administration. Effect of aspirin. Thrombosis Research 1983; IV: 137–143, (Supplement)
- Rumble R. H., Roberts M. S. Determination of aspirin and its major metabolites in plasma by high-performance liquid chromatography without solvent extraction. Journal of Chromatography 1981; 225: 252–260
- Russell T. L., Berardi R. R., Barnett J. L., O'Sullivan T. L., Wagner J. G., Dressman J. B. pH-Related changes in the absorption of dipyridamole in the elderly. Pharmaceutical Research 1994; 11: 136–143
- Williams C., Huang C. S., Erb R., Gonzalez M. A. High performance liquid chromatographic assay for plasma dipyridamole monitoring. Journal of Chromatography 1981; 225: 225–230